Patents by Inventor Sarvajit Chakravarty

Sarvajit Chakravarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220220115
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 14, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Sanjeev SONI, Puja JAISWAL, Deepak PALVE, Varun KUMAR
  • SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS
    Publication number: 20220213122
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: December 2, 2021
    Publication date: July 7, 2022
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220168313
    Abstract: Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 2, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Varun KUMAR
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220169646
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 2, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Sanjeev SONI, Puja JAISWAL, Deepak PALVE, Varun KUMAR
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20220162229
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: April 8, 2020
    Publication date: May 26, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Brahmam PUJALA, Varun KUMAR
  • Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
    Patent number: 11332473
    Abstract: This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 17, 2022
    Assignee: NUVATION BIO INC.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Brahmam Pujala, Sanjeev Soni, Puja Jaiswal, Deepak Palve, Varun Kumar
  • ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
    Publication number: 20220135598
    Abstract: The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 5, 2022
    Inventors: Brahmam Pujala, Amantullah Ansari, Shreya Sapra, Pradeep S. Jadhavar, Dhananjay Pendharkar, Sreekanth A. Ramachandran, Uzma Saeed, Abhinandan Danodia, Farha Khan, Sagar Patni, Sanjeev Soni, Ashu Gupta, Sarvajit Chakravarty, Balaji Dashrath Sathe
  • Heterocyclic compounds and uses thereof
    Patent number: 11299493
    Abstract: Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 12, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jayakanth Kankanala, Anil Kumar Agarwal, Brahmam Pujala, Sanjeev Soni, Satish K. Arya, Deepak Palve, Ashu Gupta, Varun Kumar
  • Diarylhydantoin compounds and methods of use thereof
    Patent number: 11292782
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 5, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20220071966
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: August 10, 2021
    Publication date: March 10, 2022
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • Inhibitors of integrated stress response pathway
    Patent number: 11230542
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 25, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Sebastian Bernales, Luz Marina Delgado Oyarzo, Gonzalo Esteban Núñez Vasquez, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt, Sarvajit Chakravarty
  • INHIBITORS OF ARGINASE
    Publication number: 20220017541
    Abstract: Compounds and compositions as inhibitors of arginase are provided. They may find use as therapeutic agents for the treatment of diseases or conditions associated with expression or activity of arginase.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 20, 2022
    Inventors: Sebastian BELMAR, Jennifer ALFARO, Gonzalo Esteban NÚÑEZ VASQUEZ, Sebastian BERNALES, Brahmam PUJALA, Dayanand PANPATIL, Pasha KHAN, Sarvajit CHAKRAVARTY, Gonzalo Andrés URETA DÍAZ
  • Compounds and Methods of Use
    Publication number: 20220000847
    Abstract: This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGF?) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.
    Type: Application
    Filed: May 22, 2021
    Publication date: January 6, 2022
    Applicant: Medivation Technologies LLC
    Inventors: Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
  • Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
    Patent number: 11192900
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors contanining substituted 2-pyridones and therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: December 7, 2021
    Assignee: Nuvation Bio Inc.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 11174252
    Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 16, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • Inhibitors of integrated stress response pathway
    Patent number: 11166942
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: November 9, 2021
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Luz Marina Delgado Oyarzo, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Sebastian Bernales, Sarvajit Chakravarty
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20210317102
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 14, 2021
    Inventors: Luz Marina DELGADO OYARZO, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Sebastian BERNALES, Sarvajit CHAKRAVARTY
  • Heterocyclic Compounds and Methods of Use
    Publication number: 20210317140
    Abstract: The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of PI3K?, and compounds that are dual inhibitors of both Btk and PI3K?. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3K? provides a therapeutic benefit to a patient having the disease.
    Type: Application
    Filed: October 17, 2014
    Publication date: October 14, 2021
    Applicant: Medivation Technologies, Inc.
    Inventors: Roopa RAI, Sarvajit CHAKRAVARTY, Michael John GREEN, Son Minh PHAM, Brahman PUJALA, Anil Kumar AGARWAL, Anjan Kumar NAYAK, Sweta KHARE, Rambabu GUGULOTH, Nitin Atmaram RANDIVE
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20210292285
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 23, 2021
    Inventors: Son Minh PHAM, Jiyun CHEN, Amantullah ANSARI, Pradeep S. JADHAVAR, Varshavekumar S. PATIL, Farha KHAN, Sreekanth A. RAMACHANDRAN, Anil Kumar AGARWAL, Sarvajit CHAKRAVARTY
  • ATF6 INHIBITORS AND USES THEREOF
    Publication number: 20210221803
    Abstract: Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
    Type: Application
    Filed: August 12, 2020
    Publication date: July 22, 2021
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Gonzalo Esteban NÚÑEZ VASQUEZ, Brahmam PUJALA, Balaji Dashrath SATHE, Pooja THAKRAL, Rajesh Kumar PATIDAR, Sebastian BERNALES, Sarvajit CHAKRAVARTY